The Drug Enforcement Administration (DEA) is set to launch new registration forms for state-licensed medical cannabis manufacturing, distribution, and testing businesses. This initiative follows the federal rescheduling of medical cannabis, aiming to provide these entities with federal protections, as reported by Marijuana Moment. This development expands upon an existing registration framework for dispensaries, reflecting ongoing adjustments to federal policy regarding medical cannabis business registration.
The DEA’s forthcoming launch of dedicated forms for medical cannabis business registration underscores a significant shift in federal oversight. Concurrently, the agency recently updated its official lists of controlled substances to formally classify marijuana subject to a state medical cannabis license under Schedule III. This reclassification, as previously covered by Hemp Gazette, has broader implications for the industry.
Beyond the DEA’s registration efforts, the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has also posted draft revisions to its gun purchase form. These revisions are intended to acknowledge medical marijuana’s federally legal status following the Trump administration’s rescheduling decision. These administrative adjustments by federal agencies indicate a coordinated response to the changed legal landscape for medical cannabis.
Despite these regulatory movements, concerns regarding the implementation process have been raised. Historian Emily Dufton, in an op-ed cited by Marijuana Moment, highlighted that the Trump administration’s medical cannabis rescheduling move, while intended to assist ailing seniors, may have been “rolled out quickly with vocal support but little coordination.” Dufton expressed concern that the rapid push to provide senior citizens with medical marijuana will necessitate considerable legal, scientific, and commercial infrastructures, ideally formed with clarity and coordination to avoid past errors.
Across the United States, various legislative and corporate actions reflect the evolving medical cannabis environment.
In the business sector, corporate transactions and financial reporting continue to shape the market:
International policy and scientific research also contribute to the broader understanding of cannabis regulation and its societal effects.
In Pakistan, the Economic Coordination Committee approved additional funding for the Cannabis Control and Regulatory Authority.
A recent study, as reported by Marijuana Moment, examined the effects of cannabis legalization. The research indicated that legalization reduces cannabis possession and sales arrests for both White and Black populations, though it noted that disparities are narrowed but not eliminated. The study also identified “spillover increases in hospitalizations involving cannabis and other illegal drugs” but found that “spillovers on arrests, incarcerations, and crimes involving serious violent or property offenses are insignificant or even decrease.”
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
Based in Australia, we publish industrial hemp and cannabis news, research and industry reports from around the world. Learn more about Hemp Gazette.
© Hemp Gazette